DUXAP8 and hepatocellular carcinoma: LncRNA DUXAP8, which is highly expressed in HCC and associated with poor prognosis, reduces HCC sensitivity to sorafenib induced iron death by acting on SLC7A11, a subunit of the amino acid reverse transporter system xc-, leading to sorafenib resistance [66].